Comparative Pharmacology
Head-to-head clinical analysis: DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE versus ONGLYZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE versus ONGLYZA.
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE vs ONGLYZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs incretin hormone activity, enhancing insulin secretion and decreasing glucagon release.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) to enhance glucose-dependent insulin secretion and suppress glucagon release.
Oral, 5 mg dapagliflozin / 5 mg saxagliptin once daily, with or without food.
2.5 mg or 5 mg orally once daily
None Documented
None Documented
Dapagliflozin: terminal half-life ~12.9 hours after oral dose, supporting once-daily dosing. Saxagliptin: terminal half-life ~2.5 hours for parent drug; its active metabolite has half-life ~3.1 hours; overall DPP-4 inhibition sustained for 24 hours.
Terminal elimination half-life is approximately 12.4 hours for saxagliptin. The half-life of its active metabolite is about 2.1 hours. The pharmacologically relevant half-life supports once-daily dosing.
Dapagliflozin: 75% renal (mainly as inactive glucuronide metabolite, 2% as parent drug), 21% fecal. Saxagliptin: 75% renal (metabolites, 24% as parent drug), 22% fecal. Biliary: negligible.
Approximately 75% of the administered dose is excreted in urine, with about 21% recovered as parent drug, and the remainder as metabolites. Fecal excretion accounts for about 22% of the dose, primarily as parent drug and metabolites.
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor